Pentwater Capital Management LP Buys Shares of 425,000 Surgery Partners, Inc. (NASDAQ:SGRY)

Pentwater Capital Management LP bought a new stake in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 425,000 shares of the company's stock, valued at approximately $8,997,000. Pentwater Capital Management LP owned about 0.33% of Surgery Partners at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. KBC Group NV grew its stake in Surgery Partners by 66.1% in the fourth quarter. KBC Group NV now owns 3,962 shares of the company's stock valued at $84,000 after acquiring an additional 1,577 shares during the period. MeadowBrook Investment Advisors LLC lifted its holdings in Surgery Partners by 16.6% during the fourth quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock worth $218,000 after acquiring an additional 1,460 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Surgery Partners by 279.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,762 shares of the company's stock valued at $228,000 after purchasing an additional 7,925 shares during the last quarter. Empowered Funds LLC bought a new position in Surgery Partners during the fourth quarter worth about $245,000. Finally, KLP Kapitalforvaltning AS bought a new position in Surgery Partners during the fourth quarter worth about $273,000.

Surgery Partners Trading Up 0.4 %

Shares of Surgery Partners stock opened at $21.56 on Tuesday. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -44.92, a price-to-earnings-growth ratio of 19.21 and a beta of 2.40. Surgery Partners, Inc. has a 52-week low of $19.50 and a 52-week high of $33.97. The company's 50-day simple moving average is $22.99 and its 200-day simple moving average is $23.95. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.38 by $0.01. The firm had revenue of $864.40 million during the quarter, compared to analysts' expectations of $828.09 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. As a group, equities research analysts anticipate that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Jason Eric Evans sold 26,520 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.65, for a total transaction of $680,238.00. Following the completion of the transaction, the chief executive officer now directly owns 560,698 shares of the company's stock, valued at approximately $14,381,903.70. This represents a 4.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of Surgery Partners stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $24.09, for a total transaction of $76,028.04. Following the sale, the insider now owns 63,408 shares in the company, valued at approximately $1,527,498.72. This represents a 4.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 106,622 shares of company stock worth $2,717,860 over the last quarter. 2.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $35.00 target price on shares of Surgery Partners in a research note on Tuesday, March 25th. Benchmark reaffirmed a "buy" rating and set a $35.00 target price on shares of Surgery Partners in a research note on Monday, April 21st. Finally, Macquarie cut their target price on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.75.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.

Want to see what other hedge funds are holding SGRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surgery Partners, Inc. (NASDAQ:SGRY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.